These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 33570661)
1. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis. Piao ZH; Zhou XC; Chen JY Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661 [TBL] [Abstract][Full Text] [Related]
2. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung. Berg KB; Churg A Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203 [TBL] [Abstract][Full Text] [Related]
3. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639 [TBL] [Abstract][Full Text] [Related]
4. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas. Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937 [TBL] [Abstract][Full Text] [Related]
5. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis. Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020 [TBL] [Abstract][Full Text] [Related]
6. [Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases]. Lao I; Chen Q; Yu L; Wang J Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):364-9. PubMed ID: 25208984 [TBL] [Abstract][Full Text] [Related]
7. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Attanoos RL; Dojcinov SD; Webb R; Gibbs AR Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698 [TBL] [Abstract][Full Text] [Related]
8. Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From Pulmonary Sarcomatoid Carcinoma. Terra SBSP; Roden AC; Aubry MC; Yi ESJ; Boland JM Arch Pathol Lab Med; 2021 Feb; 145(2):208-213. PubMed ID: 33501493 [TBL] [Abstract][Full Text] [Related]
9. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647 [TBL] [Abstract][Full Text] [Related]
10. [Clinical and pathologic features of extrapleural sarcomatoid mesothelioma]. Wei MC; Yang SJ Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):559-564. PubMed ID: 28810297 [No Abstract] [Full Text] [Related]
11. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Ordóñez NG Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis. Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842 [TBL] [Abstract][Full Text] [Related]
13. RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma. Hiratsuka T; Yamamoto T; Yoshizawa A; Toyokuni S; Tsuruyama T Sci Rep; 2022 Nov; 12(1):18519. PubMed ID: 36323745 [TBL] [Abstract][Full Text] [Related]
14. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions. Derakhshan F; Ionescu D; Cheung S; Churg A Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000 [TBL] [Abstract][Full Text] [Related]
15. Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall. Askan G; Basturk O Turk Patoloji Derg; 2021; 37(2):115-120. PubMed ID: 33432559 [TBL] [Abstract][Full Text] [Related]
16. [Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid]. Lyu M; Cha N; Zou YF; Leng JH; Xu L; Sun Y; Hao YY Zhonghua Bing Li Xue Za Zhi; 2018 Mar; 47(3):180-185. PubMed ID: 29534357 [No Abstract] [Full Text] [Related]
17. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742 [TBL] [Abstract][Full Text] [Related]
18. A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract. Pors J; Cheng A; Leo JM; Kinloch MA; Gilks B; Hoang L Am J Surg Pathol; 2018 Dec; 42(12):1596-1606. PubMed ID: 30148742 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731 [TBL] [Abstract][Full Text] [Related]
20. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma. Naso JR; Tsuji S; Churg A Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]